16
Aug
2010
Posted in I - Series C, Q - 3Q10, R - NORTH WEST, X - Inflammation, X - Oncology, X - PI3K, XX - WA
Calistoga Pharmaceuticals (Seattle, WA) a clinical-stage small molecule company focused on isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, closed a $40M Series C financing. Participants include Quogue Capital, Alta Partners, Amgen Ventures, Frazier Healthcare, Three Arch Partners and Latterell Venture Partners.
11
Aug
2010
28
Jul
2010
Posted in I - Series D, Q - 2Q10, R - INTERNATIONAL, X - Aptamer, X - Hematology, X - Inflammation
Noxxon Pharma (Germany) a clinical-stage biopharmaceutical company focused on the development of aptamers for the treatment of inflammation and hematological indications closed a $40M Series D financing. Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, Fcp Medical BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt [...]
19
Jul
2010
16
Jul
2010
30
Jun
2010
Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - Cardiology, X - Inflammation, X - Oncology, X - Therapeutic Platform, XX - MA
Bind Biosciences (Cambridge, MA) a preclinical-stage nanoparticle platform company focused on increased efficacy and reduced toxicity of currently marketed drugs, closed a $12.4M Series C financing. Participants include Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments and Endeavour Vision.
01
Jun
2010
Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - GI, X - Inflammation, X - NSAID, XX - MA
Logical Therapeutics (Waltham, MA) a clinical-stage biopharmaceutical company focused on rheumatoid arthritis, osteoarthritis, ankalosing spondylitis and other inflammatory diseasea, closed a $16.9M Series C financing. Participants include SV Life Sciences, Burrill & Company, Novo Ventures and Novitas Capital.
03
May
2010
22
Apr
2010
20
Apr
2010